A Study of the Effectiveness and Safety of Ramipril in the Treatment of Hypertension in Children and Adolescents

Phase 3

Terminated

• Conditions: Hypertension
• Interventions: Drug: placebo; Drug: ramipril

• Registration Number: NCT00389519
• Lead Sponsor: Pfizer

Brief Summary

The primary purpose of this study is to evaluate the blood pressure lowering effects of ramipril, an FDA-approved drug for the treatment of hypertension in adults, in children and adolescents aged 6 to 16 years with hypertension.

Detailed Description

Information is needed on the treatment of hypertension in children and adolescents with antihypertensive drugs like ramipril. The study will assess the safety and blood pressure effects of several doses of the antihypertensive drug ramipril in children and adolescents age 6-16 years. Approximately 450 children will be given placebo, or 1 of the 3 doses of ramipril. The treatment assigned will be done by chance, like flipping a coin. Approximately 120 study centers throughout the world will participate in the trial.

Each child will complete a 1- to 4-week Screening Period where they will stop taking their current blood pressure lowering drug(s), a 4-week Treatment Period where they will receive placebo or one of the ramipril doses, and a Follow-up visit 1 week after completion of the Treatment Period. Children diagnosed with hypertension according to the fourth report on the diagnosis, evaluation and treatment of high blood pressure in children and adolescents (U.S. report), will be included in the study if their blood pressure meets certain values.

Each child will complete a minimum of 6 and up to 9 clinic visits over the course of the study during which procedures and assessments of blood pressure and safety will be performed. In addition, a child's parents/guardians will be instructed to measure their child's blood pressure at home between clinic visits.

A planned interim analysis was performed after approximately 240 subjects completed the trial. The study was stopped, as permitted by protocol, after the analysis.

Study Timeline

• Study Start: 2006-10
• Study First Submitted: 2006-10-17
• Study First Submitted QC: 2006-10-18
• Study First Posted: 2006-10-19
• Primary Completion: 2007-11
• Study Completion: 2007-11
• Results First Submitted: 2010-01-21
• Results First Submitted QC: 2010-04-29
• Results First Posted: 2010-05-19
• Status Verified: 2012-06
• Last Update Submitted: 2012-06-06
• Last Update Posted: 2012-06-11

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 422

Inclusion Criteria

1. Previous, documented diagnosis of hypertension, or newly diagnosed hypertension according to the fourth report on the diagnosis, evaluation and treatment of high blood pressure in children and adolescents (United States). SiSBP greater than or equal to the 95th percentile for age, gender, and height.
2. The subject can be safely withdrawn from antihypertensive medications during the screening period, and if given placebo during the treatment period in the judgment of the Investigator.
3. The subject is male or female age 6 to 16 years (inclusive), and weighs greater than or equal to 20 kg.
4. Female subjects greater than or equal to 12 years of age, or who have had greater than or equal to 1 menstruation must: (a) have a negative serum pregnancy test at screening (i.e., subject is not pregnant), (b) not be lactating, and (c) use an acceptable method of contraception.
5. Parents/guardians are able to demonstrate their ability to (a) use a home blood pressure monitor supplied for the study to monitor their child's blood pressure, and (2) mix and administer a liquid dose of study drug if needed.

Exclusion Criteria

1. Bilateral renal artery stenosis.
2. Uncorrected coarctation of the aorta or corrected coarctation with a right arm/right leg blood pressure gradient greater than 10 mmHg.
3. Severe hypertension.
4. Renal transplantation or other previous solid organ transplantation less than 6 months prior to entering the study.
5. Subjects with nephrotic syndrome not on stable maintenance therapy of prednisone or cyclosporine.
6. A history of cardiomyopathy, clinically significant structural heart disease, or atrioventricular conduction disturbance, sick sinus syndrome, atrial flutter, atrial fibrillation, clinically significant bradycardia or an accessory bypass tract, or clinical symptoms of congestive heart failure.
7. Clinically significant hematologic, hepatobiliary, or renal disease including a Schwartz formula GFR less than 40 mL/min/1.73 m2, and/or serum potassium (K+) greater than 5.5 mEq/L.
8. History of pancreatitis (active or inactive).
9. Known sensitivity to angiotensin converting enzyme inhibitors or a history of angioneurotic edema.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	placebo	once per day
ramipril low dose	ramipril	0.3125, 0.625, or 1.25 mg once a day, based on subject weight
ramipril mid dose	ramipril	1.25, 2.5, or 5 mg once a day, based on subject weight
ramipril high dose	ramipril	5, 10, or 20 mg once a day, based on subject weight

Primary Outcome Measures

Name	Time	Method
Change From Baseline to 4 Weeks in Trough Sitting Systolic Blood Pressure	Baseline to 4 weeks	Value at end of treatment minus value at baseline, comparing the high-dose ramipril group with placebo

Secondary Outcome Measures

Name	Time	Method
Change From Baseline to 4 Weeks in Trough Sitting Diastolic Blood Pressure	Baseline to 4 weeks	Value at end of treatment minus value at baseline, comparing the high-dose ramipril group with placebo
Change From Baseline to 4 Weeks in Serum Creatinine	Baseline up to 4 weeks	Value at end of treatment (up to 4 weeks) minus value at baseline
Change From Baseline to 4 Weeks in Serum Potassium	Baseline up to 4 weeks	Value at end of treatment (up to 4 weeks) minus value at baseline
Change From Baseline to 4 Weeks in Schwartz Formula Glomerular Filtration Rate (GFR)	Baseline up to 4 weeks	Value at end of treatment (up to 4 weeks) minus value at baseline; GFR is a measure of kidney function.

Trial Locations

Locations (100)

UAMS College of Medicine/ Arkansas Children's Hospital; 🇺🇸 Little Rock, Arkansas, United States

Woodland International Research Group, LLC; 🇺🇸 Little Rock, Arkansas, United States

Impact Clinical Research; 🇺🇸 Beverly Hills, California, United States

Neufeld Medical Group; 🇺🇸 Los Angeles, California, United States

Almon Clinical Research, Inc.; 🇺🇸 Orange, California, United States

Pediatrics in Brevard; 🇺🇸 Cocoa Beach, Florida, United States

Watson Clinic Center for Research, Inc.; 🇺🇸 Lakeland, Florida, United States

Emory University; 🇺🇸 Atlanta, Georgia, United States

Medical College of Georgia; 🇺🇸 Augusta, Georgia, United States

Hawaii Pacific Health; 🇺🇸 Honolulu, Hawaii, United States

Scroll for more (90 remaining)